Loading...
Market
Percentage of US adults 50+ receiving mRNA-1083 by end of 2025
5
Resolution / Starting Odds
Under 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Over 60% • 25%
CDC vaccination data
Story
Moderna's mRNA-1083 Combo COVID-19 and Flu Vaccine Shows Stronger Immune Response in Phase 3 Trials
Jun 10, 2024, 11:10 AM
Moderna announced that its combination vaccine for COVID-19 and influenza generated a stronger immune response compared to separate shots against the two viruses. The investigational vaccine, mRNA-1083, showed positive results in a Phase 3 late-stage clinical trial, particularly in adults aged 50 and over. The Phase 3 data indicated that the combined vaccine is more effective than existing individual shots for both COVID-19 and flu. The company highlighted that the new vaccine could simplify immunization efforts by reducing the number of shots needed.
View original story
Similar markets
50 and older • 33%
30-49 • 33%
Under 30 • 33%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Over 50% vaccination rate • 25%
30-50% vaccination rate • 25%
10-30% vaccination rate • 25%
Under 10% vaccination rate • 25%
Below 20% effective • 25%
20-40% effective • 25%
41-60% effective • 25%
Above 60% effective • 25%
Under 25% • 25%
25%-50% • 25%
50%-75% • 25%
Above 75% • 25%
Below 50% effective • 25%
50-69% effective • 25%
70-89% effective • 25%
90% or more effective • 25%
Under 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
Over 75% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Below 50% effective • 33%
50% to 75% effective • 34%
Above 75% effective • 33%
Below 50% effective • 25%
50%-70% effective • 25%
71%-90% effective • 25%
More than 90% effective • 25%
Below 50% • 25%
50% to 60% • 25%
60% to 70% • 25%
Above 70% • 25%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%